Edaravone: Clinical Trials

11 trials of Edaravone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 terminated, 1 unknown. 11 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Completed 8, Terminated 2, Unknown 1
Phase 21Unknown 1

Follow Edaravone: new trials by email Literature Review of Edaravone trials Research Report on Edaravone

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
MT-1186 - ALS
Phase 3CompletedShionogi152022-10-262026-07-21
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
MT-1186, Placebo - ALS
Phase 3TerminatedShionogi2022022-01-112026-10-21
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
MT-1186, Placebo - ALS
Phase 3TerminatedShionogi3842020-11-132026-07-20
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
MT-1186 - Amyotrophic Lateral Sclerosis (ALS)
Phase 3CompletedShionogi1242020-10-292026-07-20
Safety Study of Oral Edaravone Administered in Subjects With ALS
MT-1186 - ALS
Phase 3CompletedShionogi1852019-11-182026-07-21
Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Edaravone, Riluzole - Neuromuscular Diseases
Phase 2 / Phase 3UnknownIsfahan University of Medical Sciences202017-03-162019-03-27
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
Compound Edaravone Injection, Edaravone Injection - Acute Ischemic Stroke
Phase 3CompletedJiangsu Simcere Pharmaceutical Co., Ltd.12002015-05-012017-01-16
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
MCI-186, Placebo, MCI-186 in open label phase - Amyotrophic Lateral Sclerosis (ALS)
Phase 3CompletedShionogi1372011-12-312026-07-21
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
MCI-186, Placebo of MCI-186 - Amyotrophic Lateral Sclerosis (ALS)
Phase 3CompletedShionogi1812007-01-312026-07-21
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
MCI-186, Placebo of MCI-186 - Amyotrophic Lateral Sclerosis (ALS)
Phase 3CompletedShionogi252006-12-312026-07-21
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
MCI-186, Placebo of MCI-186 - Amyotrophic Lateral Sclerosis (ALS)
Phase 3CompletedShionogi2062006-05-312026-07-21

Conditions studied

Amyotrophic Lateral Sclerosis (6)  ·  Ischemic Stroke (1)  ·  Neuromuscular Diseases (1)

Sponsors

Shionogi (9)  ·  Isfahan University of Medical Sciences (1)  ·  Jiangsu Simcere Pharmaceutical Co., Ltd. (1)

Countries

Japan (7)  ·  Canada (4)  ·  Germany (4)  ·  United States (4)  ·  Italy (3)  ·  France (2)  ·  South Korea (2)  ·  Switzerland (2)  ·  China (1)  ·  Iran (1)

Top investigators

Yongjun Wang, MD (1)

Results publications

PMID 25286015, PMID 28522181, PMID 28872913, PMID 28872914, PMID 28872915, PMID 28872918, PMID 28872920, PMID 33588596, PMID 36504406, PMID 37525592, PMID 38011420, PMID 40474686, PMID 40485494, PMID 40878665

NIH funding

2019 (1)